Patents Assigned to NeuroVive Pharmaceutical AB
  • Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation
    Patent number: 10307389
    Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: June 4, 2019
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Sarah Piel, Steven Moss
  • Protected succinates for enhancing mitochondrial ATP-production
    Patent number: 9670175
    Abstract: Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. The compounds may be of formula (I) wherein R1 is H or an optionally substituted alkyl group or a group of formula (II) and R2 is independently a group according to formula (II) where formula (II) is as defined 10 herein.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: June 6, 2017
    Assignee: NEUROVIVE PHARMACEUTICALS AB
    Inventors: Hans Georg Fliri, Rhonan Lee Ford, David Arthur Scowen, Derek Gregory Batcheller, Kari Henrik Johannes Ehinger, Mats Eskil Elmer, Magnus Joakim Hansson, Karl Fredrik Lennart Sjovall
  • Dosage form
    Patent number: 9504728
    Abstract: There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: November 29, 2016
    Assignee: NeuroVive Pharmaceutical AB
    Inventors: Matthew Alan Gregory, Steven James Moss
  • Sanglifehrin derivatives and methods for their production
    Patent number: 9271977
    Abstract: There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: March 1, 2016
    Assignee: NeuroVive Pharmaceutical AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Steven Gary Kendrew, Christine Janet Martin
  • Macrocyclic compounds and methods for their production
    Patent number: 9139613
    Abstract: There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: September 22, 2015
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson
  • Sanglifehrin based compounds
    Patent number: 9119853
    Abstract: There are provided inter alia compounds of formula (I) useful as cyclophilin inhibitors.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: September 1, 2015
    Assignee: Neurovive Pharmaceutical AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Christine Janet Martin
  • CYCLOSPORINE EMULSION
    Publication number: 20150238563
    Abstract: The present invention relates to cyclosporine emulsions containing: (i) a cyclosporine, (ii) a natural oil (long chain triglyceride), (iii) a phosphatidylcholine, (iv) glycerol, (v) a pharmaceutically tolerable alkali salt of a free fatty acid, (vi) a medium chain triglyceride-oil, (vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment and (viii) water, and to therapeutic methods using them.
    Type: Application
    Filed: March 4, 2015
    Publication date: August 27, 2015
    Applicant: NEUROVIVE PHARMACEUTICAL AB
    Inventor: Eskil Elmér
  • Compound and methods for its production
    Patent number: 9090657
    Abstract: There is provided inter alia a compound of formula (I): for use in treatment of viral infection or as an immunosuppressant.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: July 28, 2015
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventors: Matthew Alan Gregory, Steven James Moss, Barrie Wilkinson
  • Cyclosporine emulsion
    Patent number: 9040487
    Abstract: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: May 26, 2015
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventor: Eskil Elmér
  • Sanglifehrin Derivatives and Methods for Their Production
    Publication number: 20140080837
    Abstract: There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.
    Type: Application
    Filed: December 20, 2011
    Publication date: March 20, 2014
    Applicant: Neurovive Pharmaceuticals AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Steven Gary Kendrew, Christine Janet Martin
  • Macrocyclic Compounds and Methods for Their Production
    Publication number: 20140038885
    Abstract: There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.
    Type: Application
    Filed: March 29, 2012
    Publication date: February 6, 2014
    Applicant: NEUROVIVE PHARMACEUTICAL AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson
  • CYCLOSPORINE EMULSION
    Publication number: 20130323270
    Abstract: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.
    Type: Application
    Filed: September 30, 2011
    Publication date: December 5, 2013
    Applicant: NeuroVive Pharmaceutical AB
    Inventor: Eskil Elmér